1. Introduction of Axitinib
Axitinib is one kind of white crystalline powder or off-white solid. The IUPAC name of Axitinib is N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide. The product's categories are All Inhibitors; Inhibitors; Intermediates & Fine Chemicals; Pharmaceuticals; Protein Kinase Inhibitors and Activators. It is a small molecule tyrosine kinase inhibitor under development by Pfizer. Axitinib can soluble in DMSO at 33 mg/mL; soluble in ethanol at 1.7 mg/mL with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-50 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility.

2. Properties of Axitinib
Physical properties about Axitinib are:
(1)ACD/LogP: 4.15; (2)# of Rule of 5 Violations: 0; (3)ACD/LogD (pH 5.5): 4.14; (4)ACD/LogD (pH 7.4): 4.15; (5)ACD/BCF (pH 5.5): 830.65; (6)ACD/BCF (pH 7.4): 834.47; (7)ACD/KOC (pH 5.5): 4273.12; (8)ACD/KOC (pH 7.4): 4292.77; (9)#H bond acceptors: 5; (10)#H bond donors: 2; (11)#Freely Rotating Bonds: 5; (12)Polar Surface Area: 76.32 Å²; (13)Index of Refraction: 1.728; (14)Molar Refractivity: 113.45 cm³; (15)Molar Volume: 284.8 cm³; (16)Polarizability: 44.97×10^-24 cm³; (17)Surface Tension: 75.2 dyne/cm; (18)Density: 1.35 g/cm³; (19)Flash Point: 358.3 °C; (20)Enthalpy of Vaporization: 98.31 kJ/mol; (21)Boiling Point: 668.9 °C at 760 mmHg; (22)Vapour Pressure: 9.35E-18 mmHg at 25°C.

3. Structure Descriptors of Axitinib
(1)SMILES:O=C(NC)c4ccccc4Sc1ccc2c(c1)nnc2\C=C\c3ncccc3
(2)InChI:InChI=1/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+ 
(3)InChIKey:RITAVMQDGBJQJZ-FMIVXFBMBT
(4)Std. InChI:InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+
(5)Std. InChIKey:RITAVMQDGBJQJZ-FMIVXFBMSA-N

4. Uses of Axitinib
Axitinib (AG-013736) is an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), platelet derived growth factor receptor (PDGFR), and cKIT (CD117). Axitinib inhibits many targets which is including VEGFR-1, VEGFR-2, VEGFR-3, platelet derived growth factor receptor (PDGFR), and cKIT (CD117). It also can inhibit growth of breast cancer in xenograft models and has been successful in trials with renal cell carcinoma (RCC) and several other tumor types. A Phase II clinical trial showed good response in combination chemotherapy with gemcitabine for advanced pancreatic cancer.